Imperial College London

MrsTracyHarman

Faculty of MedicineNational Heart & Lung Institute

CRN Assistant Cluster Lead & Gene Therapy Programme Manager
 
 
 
//

Contact

 

+44 (0)20 7594 7932t.higgins

 
 
//

Location

 

172Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Summary

 

 

 

Mrs Tracy Harman is Assistant Cluster Lead for Cluster B (of the Medical Directorate) of the National Institute for Health Research (NIHR) Clinical Research Network (CRN), and Programme Manager for the UK CF Gene Therapy Consortium (Consortium). In her CRN role Tracy is jointly responsible for the strategic development of the Cluster B Specialties (Ear, Nose and Throat, Gastroenterology, Hepatology, Infection and Respiratory), including initiatives to facilitate delivery and development of the Clusters CRN Portfolio studies, as well as the operational management of a cohort of clinical leaders across the cluster of specialties. The NIHR CRN Cluster team is also working nationally to develop areas of emerging technology and innovation, for Cluster B these areas include Advanced Therapies, Community-Based Research and developing a volunteer workforce.

As Programme Manager for the Consortium Tracy oversees the logistical aspects of the Consortium including finances and contracting.

Tracy trained as an Administration Manager, joining Imperial College in 2000 as the Laboratory Manager for the Gene Therapy Group, becoming the Consortium's Project Manager in 2006. From 2008-2017 she managed the Royal Brompton and Harefield NHS Foundation Trust and Imperial College NIHR Biomedical Research Unit and Clinical Research Facility. She has extensive experience in financial management and contracting across numerous stakeholders, setting up and overseeing core facilities, coordinating multi-centre grant submissions, linking NIHR infrastructure nationwide and keeping the patient at the centre of research initiatives.

Publications

Journals

Alton EW, Beekman JM, Boyd AC, et al., 2016, Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis, Thorax, Vol:72, ISSN:0040-6376, Pages:137-147

Alton EWFW, Boyd AC, Davies JC, et al., 2016, Genetic Medicines for CF: Hype versus Reality, Pediatric Pulmonology, Vol:51, ISSN:8755-6863, Pages:S5-S17

Griesenbach U, Alton EWFW, Boyd AC, et al., 2015, A Phase I/IIa safety and efficacy study of nebulized liposome-mediated gene therapy for cystic fibrosis supports a multidose trial, American Journal of Respiratory and Critical Care Medicine, Vol:192, ISSN:1535-4970, Pages:1389-1392

Alton EWFW, Armstrong DK, Ashby D, 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fi brosis: a randomised, double-blind, placebo-controlled, phase 2b trial (vol 3, pg 684, 2015), Lancet Respiratory Medicine, Vol:3, ISSN:2213-2600, Pages:684-691

Alton E, Griesenbach U, Davies JC, et al., A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis, Lancet Respiratory Medicine, ISSN:2213-2619

More Publications